Background

We systematically explore the potential association between motor disorders and dementia and genetic variants. Current therapies are limited to symptom management and do not directly address genetic causes. Identifying genetic etiologies can enhance understanding of disease mechanisms and uncover novel therapeutic targets.

Participants and Design

The study has been ongoing since July 2003 and includes adults and children with motor disorders or dementia, their families, and healthy volunteers. Participants provide medical histories and blood or saliva samples, with additional blood stored in a repository when needed. Samples are coded to ensure that only NIA investigators have access, maintaining data security. The protocol involves a single visit, with follow‑up contact if further testing is required.

Expected Impact

Genetic testing using multi‑gene panels offers higher detection rates than single‑gene analyses. Identified variants can inform the development of personalized therapies or the repurposing of existing drugs. Moreover, the creation of a shared database enables global researcher access, expanding collaborative ecosystems.

Market and Industry Implications

Elucidating genetic causes is a prerequisite for biotech companies developing gene‑targeted therapeutics. The global market for genetic disease treatments is valued at several billions of dollars, and each new target enhances pipeline valuation. Consequently, pharmaceutical and biotech firms should closely monitor these research outcomes.